Intensity Therapeutics, Inc. (INTS) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 3.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: N/A
• EPS Growth: 24.79%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 47,057,728
• 10 Day Avg. Volume: 4,254,006
• 30 Day Avg. Volume: 3,956,344
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 154.23
• Enterprise Value/Gross Profit: -462.69
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: $2.50
• Price Target Upside: 900.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 24 Underperform
• Price Target: ―

Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.

Positive Factors

Innovative Cancer Treatments

Intensity Therapeutics' focus on innovative cancer treatments like INT230-6 positions it well in the oncology market, potentially leading to significant breakthroughs and partnerships.

Strategic Partnerships

Strategic partnerships with industry, government, and university hospitals enhance Intensity Therapeutics' R&D capabilities, increasing the likelihood of successful product development and commercialization.

Robust Intellectual Property Portfolio

A strong intellectual property portfolio provides Intensity Therapeutics with competitive advantages, protecting its innovations and potentially leading to lucrative licensing opportunities.

Negative Factors

Negative Profit Margins

Ongoing negative profit margins indicate high operational costs without revenue, which could strain financial resources and delay profitability.

Reliance on External Financing

Dependence on external financing for R&D poses risks if funding becomes scarce, potentially impacting the company's ability to sustain operations and advance its pipeline.

Zero Revenue Generation

The absence of revenue generation highlights the company's early-stage status, increasing reliance on successful clinical trials and partnerships for future financial stability.

Intensity Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

How the Company Makes Money

Intensity Therapeutics, Inc. generates revenue primarily through partnerships, collaborations, and licensing agreements with pharmaceutical companies and research institutions. As a clinical-stage company, its revenue model is heavily reliant on securing funding through strategic alliances and collaborations that support its research and development activities. Additionally, the company may receive milestone payments and royalties upon successful commercialization of its therapies developed in collaboration with its partners. The company's financial success is contingent on the advancement of its drug candidates through clinical trials and eventual regulatory approval, which would enable it to license or co-develop its proprietary treatments with larger pharmaceutical companies.

Intensity Therapeutics, Inc. Financial Statement Overview

Summary

Intensity Therapeutics is in its development phase, typical of biotechnology firms, with no revenue generation yet. Negative profit margins and cash flow figures highlight financial challenges, though cash reserves offer short-term stability. The company is heavily reliant on external financing to support its R&D operations.

Income Statement

Intensity Therapeutics has consistently reported zero revenue, indicating a company still in the development phase typical of biotechnology firms. The net profit margins are negative due to ongoing operational expenses without offsetting revenue. EBIT and EBITDA margins are also negative, highlighting the company's high expenditure relative to nonexistent revenue. Revenue and profit growth are absent, reflecting the company's pre-revenue stage.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio due to negative equity, which is typical for companies incurring losses during their R&D phase. Stockholders' equity is negative, indicating liabilities exceed assets. However, cash reserves are sufficient to cover immediate liabilities, which is a positive aspect for liquidity. The equity ratio is not a useful measure here given the negative equity.

Cash Flow

Operating cash flow remains negative, reflecting the cash burn typical for biotech firms in R&D. There is no free cash flow growth due to ongoing operational losses. The financing activities indicate reliance on external funding to support operations. Cash flow ratios are not meaningful due to negative income and free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-8.00K	-25.00K	-147.00K	-179.04K	0.00	0.00
EBITDA	-12.79M	-16.24M	-10.09M	-7.40M	-7.88M	-6.03M
Net Income	-12.58M	-16.27M	-10.54M	-7.45M	-7.89M	-5.96M
Balance Sheet
Total Assets	4.44M	4.78M	17.30M	1.76M	5.22M	10.15M
Cash, Cash Equivalents and Short-Term Investments	2.22M	2.59M	14.78M	1.31M	4.54M	9.32M
Total Debt	125.00K	138.00K	158.00K	4.49M	2.34M	497.48K
Total Liabilities	2.26M	1.86M	4.13M	16.85M	13.90M	11.71M
Stockholders Equity	2.18M	2.92M	13.16M	-15.10M	-8.68M	-1.56M
Cash Flow
Free Cash Flow	-11.09M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Operating Cash Flow	-11.09M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Investing Cash Flow	-6.31M	6.35M	-6.02M	0.00	0.00	4.56M
Financing Cash Flow	6.96M	2.90M	20.47M	2.25M	2.05M	6.29M

Intensity Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.29, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.

Intensity Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDRX	45 Neutral	4.10M	-0.10	0.00%	―	-100.00%	86.75%
TCRT	45 Neutral	5.34M	-0.98	0.00%	―	0.00%	79.38%
ONCO	33 Underperform	4.59M	>-0.01	-610.69%	―	-9.34%	93.84%
SLRX	30 Underperform	2.20M	-0.09	0.00%	―	0.00%	74.27%
INTS	24 Underperform		―	-334.12%	―	―	24.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Intensity Therapeutics, Inc. Corporate Events

Intensity Therapeutics Highlights Cancer Treatment Progress

On April 22, 2025, Intensity Therapeutics, Inc. announced that it will post a presentation on its website, which may be used in meetings with various stakeholders. The presentation highlights the company’s ongoing clinical trials and product development, particularly focusing on INT230-6, a novel cancer treatment. The announcement underscores the company’s strategic positioning in the cancer treatment market, showcasing its robust intellectual property portfolio and partnerships with industry, government, and university hospitals. The release also notes the company’s cost-efficient business model and the potential benefits of its innovative technology in addressing challenges associated with traditional cancer therapies.

Spark’s Take on INTS Stock

According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.

Intensity Therapeutics faces significant financial challenges typical of a pre-revenue biotech firm, with negative profit margins and reliance on external financing. Technical analysis indicates a bearish trend, with the stock trading below major moving averages. Valuation metrics are unfavorable due to the negative P/E ratio, typical of an early-stage biotech company. The overall score reflects these challenges, placing the stock at the lower end of the scoring range.

To see Spark’s full report on INTS stock, click here.